I'm thrilled to announce that our study on genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm has been published in Leukemia Journal
Thanks to all collaborators who contributed to this study.

nature.com/articles/s4137…

🧵

Out now in Leukemia Journal!

Treatment patterns for patients with AL amyloidosis post Dara CyBorD failure.

nature.com/articles/s4137…

Angela Dispenzieri Mayo Amyloid Shaji Kumar Vincent Rajkumar Morie Gertz Taxiarchis Kourelis Prashant Kapoor
Mayo Clinic Comprehensive Cancer Center Mayo Clinic Hematology-Oncology Fellowship

A brief 🧵 1/

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
MD Anderson Cancer Center #Leukemia
doi.org/10.1038/s41375… Leukemia Journal
#leusm #CML

Check out our latest paper in Leukemia Journal. We found ontogeny-specific proteomic vulnerabilities in infant and adult MLLr leukemia, e.g. Igf2 bioavailability and VLA-4-ligand interactions. A true team effort and a milestone for the lab. doi.org/10.1038/s41375…

📢Excited to share our commentary on the influence of 𝒊𝒎𝒎𝒐𝒓𝒕𝒂𝒍 𝒕𝒊𝒎𝒆 𝒃𝒊𝒂𝒔 on osteonecrosis and survival outcomes in childhood ALL! 📚 Explore our insights from the recent analysis of the COG ALL0232 trial, now featured in Leukemia Journal.
rdcu.be/dCLdp

🎉Happy to share our latest article 👉rdcu.be/dC1Kk published in Leukemia Journal!
Discover why some #CML patients hesitate to attempt #TFR despite achieving stable deep molecular response. Thanks to all collaborators and patients!
FN Brno Masarykova univerzita

😇 Refresh your knowledge on clonal #hematopoiesis and its impact on the aging osteo-hematopoietic niche.

Check out this review in Leukemia Journal:
go.nature.com/3TAgAY1

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia | Blood Cancer Journal nature.com/articles/s4140…

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms—a Danish longitudinal study | Blood Cancer Journal nature.com/articles/s4140…

Update on the management of relapsed/refractory chronic lymphocytic leukemia | Blood Cancer Journal nature.com/articles/s4140…

The evolution of preclinical models for myelodysplastic neoplasms. nature.com/articles/s4137…

Influence of co-mutational patterns in disease phenotype and clinical outcomes of CMML. nature.com/articles/s4137…

Phase III randomized trial of thalidomide in patients smoldering/ asymptomatic myeloma – updated results after 18-year follow-up

⁦Nadine Abdallah⁩ ⁦Vincent Rajkumar⁩ Shaji Kumar⁩ ⁦Taxiarchis Kourelis⁩ ⁦Mayo Myeloma⁩ nature.com/articles/s4137…

Check out oliviakovecses' amazing review in Leukemia Journal She describes the promise of #Oligonucleotide Therapeutics in AML! A great collaboration with Dr. Mercier Lady Davis Institute Thanks to the Cole Foundation for support. Oligonucleotide Therapeutics Society McGill Medicine and Health Sciences #RNA
link.springer.com/article/10.103…

Identification of novel loci for myeloma versus MGUS. nature.com/articles/s4137…

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. nature.com/articles/s4137…

Distinct clinico-molecular arterial and venous thrombosis scores for MPN risk stratification. nature.com/articles/s4137…

#CML and #pregnancy data from #European_LeukemiaNet . ⁦Leukemia Journal⁩

Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry | Leukemia nature.com/articles/s4137…

#Germline #CHEK2m in #MN . 1-2% in MDS and happens in older age. Can cause solid cancers ⁦Leukemia Journal⁩

Germline CHEK2 mutations in patients with myeloid neoplasms | Leukemia nature.com/articles/s4137…

#HMA_VEN vs #7+3 vs #Vyxeos in sAML annotated by mutations
Interesting BCOR was a good. EZH2 is bad. ⁦Leukemia Journal⁩

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML | nature.com/articles/s4137…